TG and thyroid cancer: A second major limitation relates with the fact that 25–30% of patients with differentiated thyroid cancer have endogenous circulating anti-Tg antibodies (a three-fold greater prevalence than that found in the general population) [193], which can interfere with the assays, usually producing low or undetectable Tg levels, impairing the use of this biomarker for follow-up purposes.